Similarly, the mean overall survival of 21 months observed here in POLE/POLD1 germline variant carriers with a glioblastoma compares favorably with the median overall survival of 8 months for glioblastomas according to a recent CBTRUS Statistical Report [61]. The gene discussed is POLE; the disease is glioblastoma.